NASDAQ:URGNUrogen Pharma Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Urogen Pharma Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $24.18 +0.43 (+1.81 %) (As of 06/2/2020 10:54 AM ET) Add Compare Share Today's Range$23.36Now: $24.18▼$24.1850-Day Range$21.04MA: $23.91▼$25.6452-Week Range$13.12Now: $24.18▼$38.03Volume1,494 shsAverage Volume202,931 shsMarket Capitalization$505.36 millionP/E RatioN/ADividend YieldN/ABeta1.71 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. The company's lead product candidates, UGN-101 and UGN-102 are proprietary formulations of the chemotherapy drug mitomycin, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy. It is developing its product candidates as chemoablation agents, which are designed to remove tumors by non-surgical means, to treat various forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma, and low-grade bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins. The company was incorporated in 2004 and is based in New York, New York.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingUrogen Pharma has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $45.20, Urogen Pharma has a potential upside of 86.9% from its current price of $24.18.Amount of Analyst CoverageUrogen Pharma has only been the subject of 3 research reports in the past 90 days. Previous Next 3.1 Community Rank Outperform VotesUrogen Pharma has received 331 “outperform” votes. (Add your “outperform” vote.)Underperform VotesUrogen Pharma has received 211 “underperform” votes. (Add your “underperform” vote.)Community SentimentUrogen Pharma has received 61.07% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Urogen Pharma and other stocks. Vote “Outperform” if you believe URGN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe URGN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldUrogen Pharma does not currently pay a dividend.Dividend GrowthUrogen Pharma does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Urogen Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,669.00 in company stock.Percentage Held by InsidersOnly 12.00% of the stock of Urogen Pharma is held by insiders.Percentage Held by Institutions64.41% of the stock of Urogen Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Urogen Pharma are expected to grow in the coming year, from ($6.16) to ($4.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Urogen Pharma is -4.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Urogen Pharma is -4.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioUrogen Pharma has a P/B Ratio of 2.80. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.3Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.61 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:URGN Previous Symbol CUSIPN/A CIK1668243 Webwww.urogen.com Phone646-768-9780Debt Debt-to-Equity RatioN/A Current Ratio8.58 Quick Ratio8.58Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$20,000.00 Price / Sales25,268.10 Cash FlowN/A Price / Cash FlowN/A Book Value$8.63 per share Price / Book2.80Profitability EPS (Most Recent Fiscal Year)($5.12) Net Income$-105,150,000.00 Net MarginsN/A Return on Equity-63.41% Return on Assets-58.23%Miscellaneous Employees70 Outstanding Shares20,900,000Market Cap$505.36 million Next Earnings Date8/14/2020 (Estimated) OptionableOptionable NASDAQ:URGN Rates by TradingView Receive URGN News and Ratings via Email Sign-up to receive the latest news and ratings for URGN and its competitors with MarketBeat's FREE daily newsletter. Urogen Pharma (NASDAQ:URGN) Frequently Asked Questions How has Urogen Pharma's stock been impacted by COVID-19 (Coronavirus)? Urogen Pharma's stock was trading at $23.86 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, URGN shares have increased by 1.3% and is now trading at $24.18. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Urogen Pharma? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Urogen Pharma in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Urogen Pharma. When is Urogen Pharma's next earnings date? Urogen Pharma is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020. View our earnings forecast for Urogen Pharma. How were Urogen Pharma's earnings last quarter? Urogen Pharma Ltd (NASDAQ:URGN) posted its quarterly earnings data on Thursday, May, 7th. The company reported ($1.79) earnings per share for the quarter, missing the consensus estimate of ($1.62) by $0.17. View Urogen Pharma's earnings history. What price target have analysts set for URGN? 6 equities research analysts have issued 1 year target prices for Urogen Pharma's shares. Their forecasts range from $37.00 to $57.00. On average, they expect Urogen Pharma's stock price to reach $45.20 in the next twelve months. This suggests a possible upside of 86.9% from the stock's current price. View analysts' price targets for Urogen Pharma. Has Urogen Pharma been receiving favorable news coverage? Media headlines about URGN stock have trended very positive recently, InfoTrie reports. InfoTrie ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Urogen Pharma earned a daily sentiment score of 3.5 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news aboutUrogen Pharma. Who are some of Urogen Pharma's key competitors? Some companies that are related to Urogen Pharma include Eidos Therapeutics (EIDX), Pacira Biosciences (PCRX), SAGE Therapeutics (SAGE), Madrigal Pharmaceuticals (MDGL), Aurinia Pharmaceuticals (AUPH), Passage Bio (ZNTL), Ligand Pharmaceuticals (LGND), Corcept Therapeutics (CORT), Epizyme (EPZM), Xencor (XNCR), Zymeworks (ZYME), Heron Therapeutics (HRTX), Opko Health (OPK), Zogenix (ZGNX) and Dicerna Pharmaceuticals (DRNA). View all competitors. What other stocks do shareholders of Urogen Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Urogen Pharma investors own include Crispr Therapeutics (CRSP), Micron Technology (MU), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Gilead Sciences (GILD), Kite Pharma (KITE), NVIDIA (NVDA), Exelixis (EXEL), ImmunoGen (IMGN) and Selecta Biosciences (SELB). Who are Urogen Pharma's key executives? Urogen Pharma's management team includes the following people: Ms. Elizabeth A. Barrett, Pres, CEO & Director (Age 57)Mr. Peter P. Pfreundschuh, Chief Financial Officer (Age 50)Mr. Stephen Mullennix, Chief Operating OfficerMs. Catherine Bechtold, Director of Corp. Communications & Investor RelationsDr. Sari Prutchi-Sagiv Ph.D., Marketing Director When did Urogen Pharma IPO? (URGN) raised $46 million in an IPO on Thursday, May 4th 2017. The company issued 3,500,000 shares at a price of $12.00-$14.00 per share. Jefferies and Cowen and Company served as the underwriters for the IPO and Raymond James and Oppenheimer were co-managers. What is Urogen Pharma's stock symbol? Urogen Pharma trades on the NASDAQ under the ticker symbol "URGN." Who are Urogen Pharma's major shareholders? Urogen Pharma's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.69%), Wellington Management Group LLP (5.24%), Wildcat Capital Management LLC (4.31%), Phoenix Holdings Ltd. (4.23%), State Street Corp (1.90%) and Nuveen Asset Management LLC (1.30%). Company insiders that own Urogen Pharma stock include Elizabeth A Barrett, Mark Schoenberg, Peter P Pfreundschuh and Stephen Mullennix. View institutional ownership trends for Urogen Pharma. Which institutional investors are selling Urogen Pharma stock? URGN stock was sold by a variety of institutional investors in the last quarter, including Wildcat Capital Management LLC, Meitav Dash Investments Ltd., Wellington Management Group LLP, Prosight Management LP, Morgan Stanley, Jane Street Group LLC, State Street Corp, and Shikiar Asset Management Inc.. Company insiders that have sold Urogen Pharma company stock in the last year include Mark Schoenberg, Peter P Pfreundschuh, and Stephen Mullennix. View insider buying and selling activity for Urogen Pharma. Which institutional investors are buying Urogen Pharma stock? URGN stock was bought by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Horton Capital Management LLC, SG Americas Securities LLC, Phoenix Holdings Ltd., BlackRock Inc., Coastal Bridge Advisors LLC, Geode Capital Management LLC, and Aigen Investment Management LP. Company insiders that have bought Urogen Pharma stock in the last two years include Elizabeth A Barrett, and Mark Schoenberg. View insider buying and selling activity for Urogen Pharma. How do I buy shares of Urogen Pharma? Shares of URGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Urogen Pharma's stock price today? One share of URGN stock can currently be purchased for approximately $24.18. How big of a company is Urogen Pharma? Urogen Pharma has a market capitalization of $505.36 million and generates $20,000.00 in revenue each year. The company earns $-105,150,000.00 in net income (profit) each year or ($5.12) on an earnings per share basis. Urogen Pharma employs 70 workers across the globe. What is Urogen Pharma's official website? The official website for Urogen Pharma is www.urogen.com. How can I contact Urogen Pharma? Urogen Pharma's mailing address is 400 Alexander Park, Princeton NJ, 08540. The company can be reached via phone at 646-768-9780 or via email at [email protected] This page was last updated on 6/2/2020 by MarketBeat.com Staff
